Combination treatment for first-line small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs, including liposomal irinotecan, as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have not received any previous cancer treatment.
- You have at least one tumor that can be measured on scans.
- You are in generally good physical condition (able to care for yourself).
- Your organ function (kidney, liver, blood counts) is within acceptable limits.
- If you are of childbearing age, you agree to use effective contraception during and after the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy as the first treatment for extensive-stage small cell lung cancer. It aims to see if this combination is safe and works better than standard care.
This study tests a combination of two chemotherapy drugs (irinotecan liposome and a platinum drug) plus an immunotherapy drug and a targeted therapy (anlotinib) as maintenance treatment after initial chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination keeps the cancer from growing for as long as possible.
This study tests a new combination of two drugs for small cell lung cancer that has grown after the first round of treatment. The goal is to see if the combination can slow or stop the cancer and to look for markers that predict who benefits.
This trial tests a combination of drugs as a maintenance therapy after initial chemotherapy for extensive-stage small cell lung cancer. It aims to see if this combination can help keep the cancer from growing.
This study tests whether a combination of three drugs—teniposide, cisplatin, and serplulimab—can effectively treat extensive-stage small cell lung cancer (a fast-growing type of lung cancer that has spread). Serplulimab is an immunotherapy drug designed to help your immune system fight cancer.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.